At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
In Brief
A Phase 2 clinical trial evaluating Ibrutinib and Laboratory Biomarker Analysis for Stage I Chronic Lymphocytic Leukemia and 3 related conditions. Completed, enrolled 35 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who responded to initial treatment used to reduce a cancer (front-line therapy) but have residual disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartFeb 2016
Primary CompletionDec 2023
Study CompletionJan 2026
TodayJul 2026
First PostedJan 7, 2016
Enrollment StartFeb 8, 2016
Primary CompletionDec 14, 2023
Study CompletionJan 15, 2026
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 10.5 years ago
Interventions
Ibrutinibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies